OmniAb (NASDAQ:OABI) Stock Price Breaks Below 50 Day Moving Average - Here's What Happened

OmniAb logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • OmniAb shares fell below their 50-day moving average: The stock traded as low as $4.61 and last changed hands at $4.66, below its $4.82 average.
  • Analyst views remain mostly positive: Three analysts rate the stock Buy and one rates it Sell; MarketBeat reports a Moderate Buy consensus and an average price target of $11.50.
  • The company reported quarterly EPS of -$0.12, slightly better than the -$0.13 consensus, and revenue of $3.99 million versus estimates of $3.49 million.
  • MarketBeat previews top five stocks to own in December.

OmniAb, Inc. (NASDAQ:OABI - Get Free Report) crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $4.82 and traded as low as $4.61. OmniAb shares last traded at $4.66, with a volume of 1,898,286 shares trading hands.

Analysts Set New Price Targets

A number of brokerages have commented on OABI. HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of OmniAb in a research note on Monday, August 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of OmniAb in a report on Wednesday. Finally, Leerink Partners lifted their price objective on shares of OmniAb from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 7th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $11.50.

View Our Latest Analysis on OmniAb

OmniAb Price Performance

The firm has a market cap of $679.71 million, a price-to-earnings ratio of -13.71 and a beta of 0.60. The stock has a 50-day moving average of $4.82 and a 200-day moving average of $2.94.

OmniAb (NASDAQ:OABI - Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The firm had revenue of $3.99 million for the quarter, compared to the consensus estimate of $3.49 million. OmniAb had a negative net margin of 108.11% and a negative return on equity of 16.74%. On average, equities analysts expect that OmniAb, Inc. will post -0.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in OABI. Whitefort Capital Management LP acquired a new stake in shares of OmniAb in the 2nd quarter worth about $25,211,699. BlackRock Inc. bought a new position in shares of OmniAb during the 2nd quarter valued at approximately $21,888,000. State Street Corp grew its holdings in OmniAb by 6.7% during the third quarter. State Street Corp now owns 2,277,008 shares of the company's stock valued at $11,294,000 after purchasing an additional 143,459 shares during the period. Rice Hall James & Associates LLC purchased a new stake in OmniAb in the 2nd quarter worth about $6,422,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of OmniAb in the third quarter valued at approximately $3,375,000. 72.08% of the stock is owned by institutional investors.

OmniAb Company Profile

(Get Free Report)

OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in OmniAb Right Now?

Before you consider OmniAb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.

While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines